Dr Brendan Chia Seng Hup

Dr Brendan Chia is a Specialist in Radiation Oncology. In 2010, Dr Chia received his medical degree from the National University of Ireland, and subsequently underwent specialist training in radiation oncology at the National Cancer Centre Singapore. Concurrently, he also completed his Master of Clinical Investigation at the National University of Singapore. In 2016, he was elected as a Fellow of the Royal College of Radiologists, and received an award to undergo training in clinical oncology at St Bartholomew’s Hospital, London.

During his time in London, Dr Chia received training in CyberKnife, brachytherapy, general clinical oncology, as well as prostate, gynaecological, breast, and lung oncology. In 2023, Dr Chia was awarded a proton therapy fellowship. He underwent training for the use of proton therapy for a variety of cancers at the National Centre of Oncological Hadrontherapy in Italy, and the Shizuoka Cancer Centre in Japan.

Prior to joining Raffles Hospital, Dr Chia was a consultant at National Cancer Centre Singapore and was the radiation subsite lead for Neuro-oncology. He was also the Clinical Assistant Professor at Duke-NUS Graduate Medical School, and Principal Investigator for several clinical trials. As a keen educator, Dr Chia was actively involved in training medical students and doctors, and has presented at several international conferences. He is also a guest lecturer at Nanyang Polytechnic and Singapore Institute of Management for nursing and radiation therapy students.

Dr Chia serves on the Singapore Radiological Society’s executive committee, and is involved in the Leadership Development Program for the Federation of Asian Organisations for Radiation Oncology. He has also been awarded the SingHealth Gold Service Quality Award for consecutive years.

Dr Chia’s scope of practice is the use of radiotherapy to treat a variety of cancer patients. He is proficient in the use of advanced radiotherapy techniques such as proton therapy, stereotactic radiosurgery, stereotactic ablative body radiotherapy, and volumetric modulated arc therapy to improve patient outcomes, and minimise the side effects of treatment.